Literature DB >> 23816297

Vertebral compression fracture after stereotactic body radiotherapy for spinal metastases.

Arjun Sahgal1, Cari M Whyne, Lijun Ma, David A Larson, Michael G Fehlings.   

Abstract

The use of stereotactic body radiotherapy for metastatic spinal tumours is increasing. Serious adverse events for this treatment include vertebral compression fracture (VCF) and radiation myelopathy. Although VCF is a fairly low-risk adverse event (approximately 5% risk) after conventional radiotherapy, crude risk estimates for VCF after spinal SBRT range from 11% to 39%. In this Review, we summarise the evidence and predictive factors for VCF induced by spinal SBRT, review the pathophysiology of VCF in the metastatic spine, and discuss strategies used to prevent and manage this potentially disabling complication.
Copyright © 2013 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Year:  2013        PMID: 23816297     DOI: 10.1016/S1470-2045(13)70101-3

Source DB:  PubMed          Journal:  Lancet Oncol        ISSN: 1470-2045            Impact factor:   41.316


  47 in total

1.  Effective local control of vertebral metastases by simultaneous integrated boost radiotherapy: preliminary results.

Authors:  Dorota Lubgan; Anke Ziegaus; Sabine Semrau; Ulrike Lambrecht; Sebastian Lettmaier; Rainer Fietkau
Journal:  Strahlenther Onkol       Date:  2014-11-14       Impact factor: 3.621

2.  Predictors of complications and readmission following spinal stereotactic radiosurgery.

Authors:  Daniel Lubelski; Joseph E Tanenbaum; Taylor E Purvis; Thomas T Bomberger; Courtney Rory Goodwin; Ilya Laufer; Daniel M Sciubba
Journal:  CNS Oncol       Date:  2017-07-18

3.  Safety and utility of kyphoplasty prior to spine stereotactic radiosurgery for metastatic tumors: a clinical and dosimetric analysis.

Authors:  Ori Barzilai; Natalie DiStefano; Eric Lis; Yoshiya Yamada; D Michael Lovelock; Andrew N Fontanella; Mark H Bilsky; Ilya Laufer
Journal:  J Neurosurg Spine       Date:  2017-11-03

4.  Spine metastases: are minimally invasive surgical techniques living up to the hype?

Authors:  Fahed Zairi; Marie-Helene Vieillard; Richard Assaker
Journal:  CNS Oncol       Date:  2015-06-22

5.  Modern approaches to the management of metastatic epidural spinal cord compression.

Authors:  Zain A Husain; Arjun Sahgal; Eric L Chang; Pejman Jabehdar Maralani; Charlotte D Kubicky; Kristin J Redmond; Charles Fisher; Ilya Laufer; Simon S Lo
Journal:  CNS Oncol       Date:  2017-07-18

6.  Micro-invasive surgery combined with intraoperative radiotherapy for the treatment of spinal metastasis.

Authors:  Keng Chen; Lin Huang; Zhaopeng Cai; Juntian Shi; Kaiyun You; Huiyong Shen
Journal:  Eur Spine J       Date:  2016-11-02       Impact factor: 3.134

Review 7.  Decision Making: Osteoplasty, Ablation, or Combined Therapy for Spinal Metastases.

Authors:  William Lea; Sean Tutton
Journal:  Semin Intervent Radiol       Date:  2017-06-01       Impact factor: 1.513

8.  Utilization of stereotactic ablative radiotherapy in the management of oligometastatic disease.

Authors:  J A Broomfield; J N Greenspoon; A Swaminath
Journal:  Curr Oncol       Date:  2014-06       Impact factor: 3.677

9.  Early magnetic resonance imaging biomarkers to predict local control after high dose stereotactic body radiotherapy for patients with sarcoma spine metastases.

Authors:  Daniel E Spratt; Julio Arevalo-Perez; Jonathan E Leeman; Naamit K Gerber; Michael Folkert; Neil K Taunk; Kaled M Alektiar; Sasan Karimi; John K Lyo; William D Tap; Mark H Bilsky; Ilya Laufer; Yoshiya Yamada; Joseph R Osborne
Journal:  Spine J       Date:  2016-03       Impact factor: 4.166

10.  Vertebral compression fracture after spine stereotactic body radiotherapy: a multi-institutional analysis with a focus on radiation dose and the spinal instability neoplastic score.

Authors:  Arjun Sahgal; Eshetu G Atenafu; Sam Chao; Ameen Al-Omair; Nicholas Boehling; Ehsan H Balagamwala; Marcelo Cunha; Isabelle Thibault; Lilyana Angelov; Paul Brown; John Suh; Laurence D Rhines; Michael G Fehlings; Eric Chang
Journal:  J Clin Oncol       Date:  2013-08-19       Impact factor: 44.544

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.